Introduction
The genesis and further development of immunoassay techniques during the last quarter century has permittcd the sensitive and specific quantification of a vast range of biologically important substances from small molecules such as drugs and steroid hormones to macromolecules such as viral antigens.
lmmunoassay techniques
A large number of techniques cxist though some arc more suitable than others for the measurement of a particular compound, considerations being given to its size and its concentration. Howcver, all immunoassays require two components, firstly an antibody capable of specifically binding the compound and, secondly, a tracer which permits this binding reaction to be observed. In classical radioimmunoassay (RIA) [ 11 the compound is allowed to react with an antibody, in competition with a radiolabelled antigen analogue for a limited number of antibody binding sites. T h e distribution of radiolabel between antibody bound and free fractions is a measure of the quantity of the compound present.
The choice of radiolabel depends upon the compound analysed and may be internal or external. Small molecules usually employ internal labels, for example 3H in steroids and lZsI in thyroid hormones, whereas large molecules invariably utilize an external label, 12'I. Radioiodine has a sensitivity of detection approximately 1000-fold that of tritium and is thus universally employed.
However, in RIA systems sensitivity is not necessarily limited by the sensitivity of detection of the label but is ultimately dependent upon the equilibrium constant of the antibody-antigen Correspondence: Dr I. Weeks reaction [2] . This is not the case when immunoradiometric assays (IRMA) are employed, in which excess labelled antibody is used as the binding reagent, since here sensitivity is ultimately determined by the specific activity of the labelled antibody, provided that the non-specific binding is low. The two-site assay is the most favoured form of IRMA [3] , which involves simultaneous binding of the compound by both labelled and solid-phase antibody derivatives; its concentration is thus directly proportional to the amount of solid-phase bound radioactivity obtained after immune complex separation. This type of assay has several advantages over RIA: in particular, rapid reaction kinetics due to the use of excess binding reagents. In practical terms the sensitivity is limited ,by the sensitivity of detection of l r s I and is frequently not much greater than that of carefully optimized RIA.
Labelled antibody immunoassays for haptens require the use of competitive binding architecture because the small size of the molecule precludes the simultaneous antibody binding required by two-site methodology. Here the labelled antibody competes with the compound and a suitable solidphase antigen derivative to form soluble and insoluble immune complexes, the tracer activity in the latter being inversely proportional to the concentration of the compound.
Labels
Problems of performance and stability are common to all immunoassays which utilize Iz5I since it is a high-energy y-emitter with a half-life of only 60 days. T h e shelf-life of reagents based on this isotope is frequently much less than this, owing to radiolytic damage of the labelled molecule. The limitations of these assay systems together with the emotive bias against the use of radioisotopes in many countries have stimulated thc search for non-radioactive labels suitable for use as immunoassay probes.
Until recently non-isotopic labels have failed to demonstrate the sensitivity attainable with Iz5I, far T h e time-dependent and temperature-dependent enzyme reactions which constitute the endpoint of enzyme immunoassay systems impart complexity to these systems which is unacceptable to the busy routine immunoassay laboratory. Further precise, high-sensitivity assays have not been demonstrated even where enzyme cycling reactions are used to provide large amplification factors. Enzyme immunoassays have been described which utilize a chemiluminescent endpoint. as opposed to the more conventional colorimetric or fluorimetric end-point determinations.
Here a peroxidase-labelled antibody or antigen/ hapten is measured via its catalytic effect on luminol [4, 51 (see below). Such techniques are subject to a high degree of non-specific interference, which limits sensitivity, although recently a benzothiazole enhanced system has been described which is purported to yield increased sensitivity compared with conventional luminol end-points [6] .
Potentially time-resolved fluorescence immunoassay is a highly sensitive technique, though in practice, even with sophsticated machinery and chemical manipulation which detract from its routine applicability, assay sensitivity is no greater than with lZsI based immunoassays.
Chemiluminescent molecules
Research into the use of chemiluminescent molecules as immunoassay probes has been carried out over the last decade but only recently has the clinical utility of such assays been demonstrated. Chemiluminescence differs from fluorescence in that it involves excited state formation as the product of an exoergic chemical reaction. The excited state product molecule subsequently relaxes to its ground state with the emission of photons. Several classes of organic molecules exhibit chemiluminescence under appropriate conditions, the earliest synthetic molecule studied being luminol [7] . Another type of chemiluminescent molecule is that based upon the aryl acridinium ester moiety. T h e reaction conditions required to bring about chemiluminescence of these two classes of molecules are quite different (Fig. 1) .
Undcr aqueous conditions luminol requires the presence of alkaline hydrogen peroxide solution and a catalyst. T h e reaction is somewhat nonspecific in that several active oxygen species are capable of initiating luminol chemiluminescence [8, 91; further, a wide range of species can catalyse The chemiluminescent reaction of aryl acridinium esters does not require a catalyst and proceeds in the presence of dilute alkaline hydrogen peroxide only. The reaction is postulated to be a concerted miiltiple bond cleavage via a dioxetanone intermediate to yield a vibronically excited molecule of N-methyl acridone, which is dissociated from the rest of the molecule before photonic emission [12] . The kinetics of the chemiluminescent reaction can be varied by altering the chemical conditions such that photon emission takes place within seconds or minutes depending upon requirements. For a rapid assay system it is desirable that the measurement is fast in order to permit rapid throughput.
The emitted photons can be precisely and accurately quantified by using commercially available luminometers, which operate in either a digital photon counting mode or an analogue current measurement mode. Presently these are not solely designed for immunoassay purposes and vary considerably in terms of their specification and performance.
Immunoassays based on chemiluminescent labels
Much of the early work concerned with the development of chemiluminescence immunoassays involved the use of luminol and isoluminol derivatives as labels. However, though viable immuno-assays for steroids were developed [13-171 it became apparent that such labels were unable to yield highly sensitive immunoassays. This is undoubtedly due to the fact that luminol chemiluminescence is prone to interference by a large number of factors arising from the catalytic requirements of the reaction and microenvironmental quenchindenhancement. The susceptibility of the emission to these influences has been utilized in some of the early assays for the development of homogeneous systems, that is assays requiring no separation of bound and free tracer before quantification [18, 191. Here use has been made of the quenching or enhancement of the emission upon binding to antibody; however, the effect on the emission is system dependent and rather unpredictable.
Another type of homogeneous chemiluminescence immunoassay relies upon the phenomenon of radiationless energy transfer. Here, the antigen and antibody are labelled with a chemiluminescent molecule and a fluorescent molecule respectively. These species are chosen such that the emission spectrum of the former overlaps with the absorption spectrum of the latter. Upon immune complex formation emission occurs at the emission wavelength of the fluorophor rather than at the wavelength of the chemiluminescent molecule. The ratio of the intensity of the two wavelengths, measured with a dual wavelength luminometer [20] , is thus a measure of the quantity of compound to be analysed introduced into the reaction. In common with other homogeneous non-radioisotopic immunoassays the sensitivity of these systems is insufficient for their adoption as universal immunoassay procedures and so heterogeneous systems are obligatory where high sensitivity is required.
Since acridinium ester chemiluminescence occurs under mild conditions and arises from a dissociative reaction the potential for interference is considerably reduced. [24] .
T h e ICMA for thyrotrophin (TSH) is an example of the improvement in performance attainable with this technology as compared with other methods (Table 1 ). In this assay the sample to be measured (100 11.1) is incubated with high specific activity acridinium ester labelled monoclonal antibodies to TSH for 2 h at room temperature. Solid-phase, polyclonal anti-TSH antibodies are then added and the mixture is incubated for a further hour. T h e solid-phase immune complexes are then separated, for example by centrifugation, and their chemiluminescence activity measured luminometrically after automatic injection of alkaline hydrogen peroxide solution. Photon counts are integrated over 2 s, the intensity being directly proportional to the concentration of TSH in the sample (Fig. 2) . The sensitivity of this assay permits complete discrimination between euthyroid and thyrotoxic subjects (Fig. 3) . It is frequently argued that sensitive TSH measurement is superior to the measurement of thyroid hormones as an index of thyroid function. In practice, however, the usefulness of conventional TSH assays is restricted to the confirmation of a diagnosis of primary hypothyroidism and the exclusion of a diagnosis of hyperthyroidism in conjunction with the thyroliberin (TRH) test. These limitations arise owing to the insensitivity of immunoassays based upon the use of 1251 labels. Even the most recently + Approximation based on in-house experiments. available IRMA d o not exhibit a sufficient level of performance to permit complete discrimination of thyrotoxic patients from euthyroid subjects. Such assays therefore cannot act as an efficient first-line test of thyroid function whereas the ICMA exhibits the performance necessary for this role. Measurement of thyroid hormones will still play an essential part in the biochemical diagnosis of thyroid disorders and it is now possible to use chemiluminescent labelled antibody technology for the quantification of low molecular weight compounds such as thyroxine as well as for polypeptides. An example of such an assay involves the competitive reaction of an acridinium ester labelled antibody raised to thyroxine with the sample and a solid-phase derivative of T4. After incubation of the mixture for 40 min and separation of the solid-phase immune complexes, the chemiluminescence activity in the latter is quantified luminometrically. The intensity of the emission is inversely proportional to the concentration of T4 in the sample. Using this architecture it has been possible to engineer immunoassays for the measurement of both total and free thyroxine.
Figs. 4 and 5 show dose-response curves for total and free thyroxine (fT4) assays respectively and it can be seen that both assays cover the clinically important range for the hormones. The measurement of the free hormone is probably more useful since it represents the biologically important fraction of the hormone pool. T h e measurement of fT4 is technically difficult but has been simplified to a certain extent by the introduction of labelled hormone analogues which bind to the antibody but not to serum proteins. However, in practice, assays based on these tracers are frequently prone to interference by non-specific factors [25, 261. The labelled antibody assay described here appears to be unaffected by such factors, as indicated by Fig. 6 . fT4 was measured by this and an analogue method in normal subjects and in euthyroid patients with chronic renal disease. T h e ranges of results obtained for both groups were not significantly different by use of the chemiluminescent labelled antibody assay. However, the analogue method showed an apparent decrease in fT4 concomitant with the low serum albumin concentrations seen in these patients. Equilibrium dialysis studies show that euthyroid patients with this class of non-thyroidal illness have normal f l 4 levels. Their euthyroid clinical status has also been confirmed with a TSH-ICMA [23] .
Conclusions
Chemiluminescent immunoassays have reached the stage where they are capable of being used for the quantification of a wide range of substances in a routine laboratory environment. Not only d o these assays exhibit performance equivalent to RIA or IRMA but in some cases far surpass conventional methods. This property accompanies the benefits of stable, non-radioactive systems to yield tests which are functionally and emotively desirable.
T h e high level of commercial interest in this technology over recent years has meant that chemiluminescent immunoassay systems employing various chemistries and instrumentation will appear in the marketplace within the coming year. It remains to be seen which technology becomes widely accepted by the routine laboratory.
